New data show how ICER ’s value framework could prevent or delay access to treatments for Medicaid patients across the country

Anew analysis from Xcenda applied the Institute for Clinical and Economic Review ’s (ICER) value assessments to state Medicaid programs inCalifornia,Massachusetts,Maryland,NevadaandNew York. The study found these one-size-fits-all value assessments could prevent or delay access to prescriptions to treat serious, complex conditions like multiple sclerosis (MS), rheumatoid arthritis (RA), non-small cell lung cancer (NSCLC) and psoriasis.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Access Medicaid Value-Driven Health Care The Value Collaborative Source Type: news